Chemokine receptors: Therapeutic potential in asthma

Treatments in Respiratory Medicine

Volumn 5, Issue 3, 2006, Pages 159-166

  Lloyd, Clare M ^a   Brown, Zarin ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; BERTILIMUMAB; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CYTOKINE; G PROTEIN COUPLED RECEPTOR; CYTOKINE RECEPTOR; EOTAXIN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; CELL INFILTRATION; CLINICAL TRIAL; CROSS REACTION; DRUG INDUSTRY; DRUG TOLERANCE; EOSINOPHIL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MAST CELL; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RODENT; SIGNAL TRANSDUCTION; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; HYPERSENSITIVITY;

ANIMALS; ASTHMA; CHEMOKINE CCL11; CHEMOKINES; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE;

EID: 33646736787     PISSN: 11763450     EISSN: 11763450     Source Type: Journal    
DOI: 10.2165/00151829-200605030-00002     Document Type: Review

References (67)

1. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001; 2: 129-34
2. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Mol Med Today 2000; 6: 365-72
3. Ying S, Robinson DS, Meng Q, et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C- C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999; 163: 3976-84
4. h2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304
5. Gonzalo JA, Lloyd CM, Wen D, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airways hyperresponsiveness. J Exp Med 1998; 188: 157-67
6. Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999; 190: 895-902
7. Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346: 1699-705
8. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy 2005; 60: 23-9
9. Lloyd C. Chemokines in allergic lung inflammation. Immunology 2002; 105: 144-54
10. D'Ambrosio D. Targeting chemoattractant receptors in allergic inflammation. Curr Drug Targets Inflamm Allergy 2005; 4: 163-7
11. Palframan RT, Collins PD, Severs NJ, et al. Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med 1998; 188: 1621-32
12. Gu L, Tseng S, Horner RM, et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404: 407-11
13. Jamieson T, Cook DN, Nibbs RJB, et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 2005; 6: 403-11
14. Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in reacvitro and in vivo. J Infect Dis 2004; 189: 1419-30
15. Openshaw PJM, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005; 18: 541-55
16. Miller AL, Strieter RM, Gruber AD, et al. CXCR2 Regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction. J Immunol 2003; 170: 3348-56
17. Lamblin C, Gosset P, Tillie-Leblond I, et al. Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med 1998; 157: 394-402
18. Schuh JM, Blease K, Hogaboam CM. CXCR2 is necessary for the development and persistence of chronic fungal asthma in mice. J Immunol 2002; 168: 1447-56
19. Ponath PD, Qin S, Post TW, et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996; 183: 2437-48
20. Daugherty BL, Siciliano SJ, DeMartino J, et al. Cloning, expression and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996; 183: 2349-54
21. Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarised T helper 1 and 2 lymphocytes. J Exp Med 1998; 187: 875-83
22. Teran LM, Davies DE. The chemokines: their potential role in allergic inflammation. Clin Exp Allergy 1996; 26: 1005-19
23. Sabroe I, Peck MJ, Jan Van Keulen B, et al. A small molecule antagonist of the chemokine receptors CCR1 and CCR3: potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 2000; 275: 25985-92
24. De Lucca GV, Kim UT, Vargo BJ, et al. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. J Med Chem 2005; 48: 2194-211
25. Zhang L, Soares MP, Guan Y, et al. Functional expression and characterization of macaque C-C chemokine receptor 3 (CCR3) and generation of potent antagonistic anti-macaque CCR3 monoclonal antibodies. J Biol Chem 2002; 277: 33799-810
26. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-8
27. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305: 1776-9
28. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112: 1029-36
29. Gonzalo JA, Pan Y, Lloyd CM, et al. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. J Immunol 1999; 163: 403-11
30. Kawasaki S, Takizawa H, Yoneyama H, et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J Immunol 2001; 166: 2055-62
31. Chvatchko Y, Hoogewerf AJ, Meyer A, et al. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 2000; 191: 1755-64
32. Pilette C, Francis JN, Till SJ, et al. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur Respir J 2004; 23: 876-84
33. Purandare AV, Gao A, Wan H, et al. Identification of chemokine receptor CCR4 antagonist. Bioorg Med Chem Lett 2005; 15: 2669-72
34. Newhouse B, Allen S, Fauber B, et al. Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists. Bioorg Med Chem Lett 2004; 14: 5537-42
35. Chensue SW, Lukacs NW, Yang TY, et al. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in cc chemokine receptor 8 knockout mice. J Exp Med 2001; 193: 573-84
36. Goya I, Villares R, Zaballos A, et al. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J Immunol 2003; 170: 2138-46
37. Chung CD, Kuo F, Kumer J, et al. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J Immunol 2003; 170: 581-7
38. Bochner BS, Hudson SA, Xiao HQ, et al. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. J Allergy Clin Immunol 2003; 112: 930-4
39. Liu L, Jarjour NN, Busse WW, et al. Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma. Am J Respir Crit Care Med 2004; 169: 1118-24
40. Brightling CE, Ammit AJ, Kaur D, et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 2005; 171: 1103-8
41. Heise CE, Pahuja A, Hudson SC, et al. Pharmacologic characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther 2005; 313: 1263-71
42. Gonzalo JA, Lloyd CM, Peled A, et al. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol 2000; 165: 499-508
43. Lukacs NW, Berlin A, Schols D, et al. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160: 1353-60
44. Proudfoot AE, Power CA, Hoogewerf AJ, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996; 271: 2599-603
45. Chvatchko Y, Proudfoot AEI, Buser R, et al. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol 2003; 171: 5498-506
46. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophage and lymphocytes by a novel CCR5 antagonist. Science 1997; 276: 276-9
47. Nibbs RJ, Salcedo TW, Campbell JD, et al. C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap. J Immunol 2000 Feb 1; 164 (3): 1488-97
48. Elsner J, Petering H, Hochstetter R, et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 1997; 27: 2892-8
49. Elsner J, Mack M, Bruhl H, et al. Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 2000; 275: 7787-94
50. Homey B, Zlotnik A. Chemokines in allergy. Curr Opin Immunol 1999; 11: 626-34
51. Heath H, Qin S, Wu L, et al. Chemokine receptor usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997; 99: 178-84
52. Justice JP, Borchers MT, Crosby JR, et al. Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am J Physiol Lung Cell Mol Physiol 2003; 284: L169-78
53. Ding C, Li J, Zhang X. Bertilimumab Cambridge Antibody Technology Group. Curr Opin Investig Drugs 2004; 5: 1213-8
54. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278: 290-4
55. Sozzani S, Allavena P, Vecchi A, et al. Chemokine receptors: interaction with HIV-1 and viral-encoded chemokines. Pharm Acta Helv 2000; 74: 305-12
56. Gao JL, Murphy PM. Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J Biol Chem 1994; 269: 28539-42
57. Johnson Z, Kosco-Vilbois MH, Herren S, et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 2004; 173: 5776-85
58. Johnson Z, Schwarz M, Power CA, et al. Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol 2005; 26: 268-74
59. Wymann MP, Bjorklof K, Calvez R, et al. Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem Soc Trans 2003; 31: 275-80
60. Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005; 17: 141-9
61. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003; 3: 426-34
62. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3: 831-44
63. Kumar S, Boehm J, Lee JC. P38 map kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-26
64. Scandella E, Men Y, Gillessen S, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100: 1354-61
65. Wong M, Uddin S, Majchrzak B, et al. RANTES activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 2001; 276: 11427-31
66. Roshak AK, Callahan JF, Blake SM. Small-molecule inhibitors of NF-[kappa]B for the treatment of inflammatory joint disease. Curr Opin Pharmacol 2002; 2: 316-21
67. Gutierrez-Ramos JC, Lloyd C, Kapsenberg ML, et al. Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol Rev 2000; 177: 31-42